Discontinued — last reported Q4 '23
Products & Services · Payable Due To Termination Agreement
LEQEMBI Collaboration — Payable Due To Termination Agreement
Biogen LEQEMBI Collaboration — Payable Due To Termination Agreement remained flat by 0.0% to $31.00M in Q4 2023 compared to the prior quarter. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementSegment
CategoryRisk
SignalLower is better
VolatilityVolatile
First reportedQ1 2023
Last reportedQ4 2023
How to read this metric
An increase signals a higher financial burden or settlement cost related to exiting a partnership, which may negatively impact liquidity.
Detailed definition
This represents the financial liability recognized due to the potential or actual termination of a collaborative agreeme...
Peer comparison
Similar to contingent liabilities or exit costs found in other R&D-heavy industries when partnerships dissolve.
Metric ID:
biib_segment_leqembi_collaboration_payable_due_to_termination_agreementHistorical Data
4 periods
| Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | |
|---|---|---|---|---|
| Value | $31.00M | $31.00M | $31.00M | $31.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% |
Range$31.00M – $31.00M
Current Streak3+ quarters growth
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Biogen's leqembi collaboration — payable due to termination agreement?
- Biogen (BIIB) reported leqembi collaboration — payable due to termination agreement of $31.00M in Q4 2023.
- What does leqembi collaboration — payable due to termination agreement mean?
- The amount of money owed to a partner resulting from the end or cancellation of a product collaboration agreement.